SunTrust Banks Analysts Decrease Earnings Estimates for Endo International PLC (NASDAQ:ENDP)

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Investment analysts at SunTrust Banks reduced their Q4 2019 earnings per share (EPS) estimates for shares of Endo International in a note issued to investors on Monday, November 11th. SunTrust Banks analyst G. Gilbert now expects that the company will post earnings of $0.55 per share for the quarter, down from their previous forecast of $0.61. SunTrust Banks also issued estimates for Endo International’s Q1 2020 earnings at $0.59 EPS, Q4 2020 earnings at $0.66 EPS, FY2020 earnings at $2.41 EPS, FY2021 earnings at $2.20 EPS and FY2022 earnings at $1.28 EPS.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.07. Endo International had a negative return on equity of 99.08% and a negative net margin of 16.89%. The company had revenue of $729.00 million during the quarter, compared to analyst estimates of $709.01 million. During the same quarter in the previous year, the company posted $0.71 earnings per share. Endo International’s revenue was down 2.1% compared to the same quarter last year.

Several other analysts have also commented on the company. BidaskClub raised Endo International from a “strong sell” rating to a “sell” rating in a report on Friday, October 18th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $6.00 price objective on shares of Endo International in a report on Thursday, August 8th. Morgan Stanley set a $2.00 price objective on Endo International and gave the stock a “sell” rating in a report on Friday, August 9th. Mizuho reaffirmed a “hold” rating and issued a $6.00 price objective on shares of Endo International in a report on Wednesday, August 7th. Finally, ValuEngine lowered Endo International from a “hold” rating to a “sell” rating in a report on Thursday, November 7th. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $7.78.

Shares of ENDP opened at $4.29 on Wednesday. Endo International has a one year low of $1.97 and a one year high of $13.64. The firm has a market capitalization of $981.94 million, a P/E ratio of 1.48 and a beta of 1.41. The business has a fifty day moving average of $4.09 and a 200 day moving average of $4.28.

Large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its holdings in Endo International by 56.4% during the second quarter. Russell Investments Group Ltd. now owns 167,064 shares of the company’s stock valued at $689,000 after purchasing an additional 60,234 shares during the period. United Services Automobile Association lifted its position in shares of Endo International by 6.4% in the second quarter. United Services Automobile Association now owns 218,890 shares of the company’s stock valued at $902,000 after acquiring an additional 13,126 shares in the last quarter. Meeder Asset Management Inc. lifted its position in shares of Endo International by 47.1% in the second quarter. Meeder Asset Management Inc. now owns 37,887 shares of the company’s stock valued at $156,000 after acquiring an additional 12,127 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Endo International by 61.2% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 3,063,703 shares of the company’s stock valued at $12,622,000 after acquiring an additional 1,163,289 shares in the last quarter. Finally, Commonwealth Bank of Australia lifted its position in shares of Endo International by 41.6% in the second quarter. Commonwealth Bank of Australia now owns 66,400 shares of the company’s stock valued at $273,000 after acquiring an additional 19,500 shares in the last quarter. 95.90% of the stock is owned by institutional investors and hedge funds.

In other Endo International news, Director Roger H. Kimmel sold 25,000 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $4.09, for a total transaction of $102,250.00. Following the completion of the sale, the director now owns 123,309 shares of the company’s stock, valued at $504,333.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Article: How to Invest in a Bull Market

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.